Shanghai Hile Bio-tech (603718) - Total Liabilities
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has total liabilities worth CN¥105.96 Million CNY (≈ $15.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shanghai Hile Bio-tech (603718) cash conversion ratio to assess how effectively this company generates cash.
Shanghai Hile Bio-tech - Total Liabilities Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Shanghai Hile Bio-tech to evaluate the company's liquid asset resilience ratio.
Shanghai Hile Bio-tech Competitors by Total Liabilities
The table below lists competitors of Shanghai Hile Bio-tech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Power Wind Health Industry Incorporated
TW:8462
|
Taiwan | NT$9.35 Billion |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
USA | $888.05 Million |
|
Samkang M&T Co.Ltd
KQ:100090
|
Korea | ₩699.23 Billion |
|
63 moons technologies limited
NSE:63MOONS
|
India | Rs2.89 Billion |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $27.31 Million |
|
GRM Overseas Limited
NSE:GRMOVER
|
India | Rs3.86 Billion |
|
Hangzhou Landscape Architecture Design Institute Co Ltd
SHE:300649
|
China | CN¥402.17 Million |
|
Advanced Ceramic X
TWO:3152
|
Taiwan | NT$437.44 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Shanghai Hile Bio-tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Hile Bio-tech market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Hile Bio-tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual total liabilities of Shanghai Hile Bio-tech from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥123.65 Million ≈ $18.09 Million |
-74.40% |
| 2023-12-31 | CN¥482.96 Million ≈ $70.67 Million |
+19.77% |
| 2022-12-31 | CN¥403.25 Million ≈ $59.01 Million |
-52.94% |
| 2021-12-31 | CN¥856.90 Million ≈ $125.39 Million |
+3.92% |
| 2020-12-31 | CN¥824.54 Million ≈ $120.66 Million |
+16.34% |
| 2019-12-31 | CN¥708.72 Million ≈ $103.71 Million |
-1.95% |
| 2018-12-31 | CN¥722.81 Million ≈ $105.77 Million |
+37.20% |
| 2017-12-31 | CN¥526.83 Million ≈ $77.09 Million |
+11.02% |
| 2016-12-31 | CN¥474.55 Million ≈ $69.44 Million |
+71.31% |
| 2015-12-31 | CN¥277.01 Million ≈ $40.54 Million |
+188.62% |
| 2014-12-31 | CN¥95.98 Million ≈ $14.04 Million |
-4.19% |
| 2013-12-31 | CN¥100.17 Million ≈ $14.66 Million |
+7.97% |
| 2012-12-31 | CN¥92.78 Million ≈ $13.58 Million |
-5.61% |
| 2011-12-31 | CN¥98.29 Million ≈ $14.38 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more